Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    PLoS One. 2010 Apr 1;5(4):e9934. doi: 10.1371/journal.pone.0009934.

    Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity.

    Source

    Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.

    Abstract

    BACKGROUND:

    Hsp90 is an essential molecular chaperone that is also a novel anti-cancer drug target. There is growing interest in developing new drugs that modulate Hsp90 activity.

    METHODOLOGY/PRINCIPAL FINDINGS:

    Using a virtual screening approach, 4-hydroxytamoxifen, the active metabolite of the anti-estrogen drug tamoxifen, was identified as a putative Hsp90 ligand. Surprisingly, while all drugs targeting Hsp90 inhibit the chaperone ATPase activity, it was found experimentally that 4-hydroxytamoxifen and tamoxifen enhance rather than inhibit Hsp90 ATPase.

    CONCLUSIONS/SIGNIFICANCE:

    Hence, tamoxifen and its metabolite are the first members of a new pharmacological class of Hsp90 activators.

    PMID:
    20376192
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2848575
    Free PMC Article

    Images from this publication.See all images (4)Free text

    Figure 1
    Figure 2
    Figure 3
    Figure 4

      Supplemental Content

      Icon for Public Library of Science Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk